id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-270723-cjfglili	Fteiha, Bashar	QTc prolongation among hydroxychloroquine sulfate‐treated COVID‐19 patients: An observational study	2020-10-15		.txt	text/plain	3317	191	50	Age > 65 years, congestive heart failure, severity of disease, C‐reactive protein level, hypokalemia and furosemide treatment, were all associated with QTc prolongation. CONCLUSION: In patients treated with HCQ, QTc prolongation was associated with the presence of traditional risk factors such as hypokalemia and furosemide treatment. All rights reserved Univariate analysis revealed that in COVID-19 patients treated with HCQ, age above 65 years, severe or critical illness, congestive heart failure, hypokalemia, furosemide treatment and increased CRP level were all significantly associated with the composite endpoint (Table 2) . However, multivariate analysis in this small dataset also suggested that in COVID-19 patients treated with HCQ, concomitant hypokalemia and furosemide treatment were strongly associated with QTc prolongation. In conclusion, our study shows that QTc prolongation among HCQ-treated patients was associated with traditional, modifiable risk factors such as hypokalemia and furosemide treatment which are both commonly observed in COVID-19 patients.	./cache/cord-270723-cjfglili.txt	./txt/cord-270723-cjfglili.txt